Table 2A

Concomitant LLT in the 12 months preceding initiation of treatment with alirocumab (FAS; n=200)*

LLT during 12 months before baseline
N (%)Daily dose (mg)
mean (95% CI)
LDL-C on max dose (mg/dL)
mean (95% CI)
Atorvastatin†144 (72.0)48.3 (44.0 to 52.5)152.6 (126.1 to 179.1)
Simvastatin†82 (41.0)36.7 (32.2 to 41.2)164.5 (146.2 to 182.8)
Rosuvastatin†44 (22.0)16.4 (12.2 to 20.6)119.0 (105.5 to 132.4)
Fluvastatin†27 (13.5)33.1 (26.0 to 40.2)140.4 (130.4 to 150.5)
Pravastatin†21 (10.5)25.4 (19.2 to 31.6)133.9 (113.0 to 154.9)
Ezetimibe1 (0.5)10.0129.0
Any statin + Ezetimibe147 (73.5)n.a.143.0 (119.9 to 166.1)
Other/none‡11 (5.5)n.a.n.a.
  • The numbers reflect a 12-month period with potential switches between statins. Thus, the numbers are much higher than if you look at a single timepoint, eg, baseline.

  • *Potentially time-displaced for the 12 months prior to inclusion.

  • †Alone or in combination.

  • ‡Including colesevelam hydrochloride.

  • FAS, full analysis set; LDL-C, low density lipoprotein cholesterol; LLT, lipid-lowering therapy.